safety
antigenicity
inactivated
influenza
virus
vaccines
children
trials
monovalent
bivalent
new
jersey
hswn
victoria
virus
vaccines
washington
c
safety
antigenicity
monovalent
bivalent
new
jersey
nj
hssn
victoria
inactivated
influenza
virus
vaccines
studied
children
aged
three
years
recruitment
families
knew
study
team
professionally
involved
close
continuing
care
likely
volunteer
studies
unfamiliar
team
institution
antibody
responses
systemic
reactions
occurred
often
administration
inactivated
whole
virus
vaccine
split
virus
vaccine
significant
titers
greater
equal
hemagglutination
inhibiting
antibody
nj
virus
occurred
normal
children
three
years
age
received
two
doses
vaccine
whole
split
however
insufficient
numbers
children
achieved
reasonable
antibody
titer
greater
equal
one
dose
vaccine
